Chiral Announces Arbor Acquisition
Chiral Technologies Inc. has announced the acquisition of Arbor Biosciences.
Chiral Technologies Inc. (Pennsylvania, USA) has announced the acquisition of Arbor Biosciences (Michigan, USA).
Founded in 2006 by University of Michigan Prof. Erdogan Gulari and Dr. Jean-Marie Rouillard, Arbor Biosciences has evolved from producing custom DNA microarrays to generating oligonucleotide pools using proprietary massively parallel DNA synthesis technology.
“This is a very exciting time as we are moving Arbor Biosciences to the next level,” stated Jean-Marie Rouillard, CSO and co-founder at Arbor Biosciences “The additional investments by Chiral will help accelerate our growth and deliver innovative, cost-effective solutions to our clients in the biotechnology and life sciences markets faster than previously planned. It will also open up access to new markets.”
The company primarily produce targeted sequencing panels, which are complemented by their services division. Arbor recently expanded into synthetic biology with a cellâfree expression system using linear DNA as a template for rapid protein expression.
“As we diversify our product portfolio to serve the needs of biopharma, Arbor Biosciences delivers the molecular biology foundation to fuel that growth,” said Joseph Barendt, President of Chiral Technologies, Inc.
Arbor Biosciences will continue to operate at its current location in Ann Arbor as a wholly owned subsidiary of Daicel Corporation and managed by Chiral Technologies, Inc. The entire Arbor Biosciences team will remain in place, including co-founders Gulari and Rouillard.
For more information, please visit: www.chiraltech.com or www.arborbiosci.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
